Target Name: TMCO5A
NCBI ID: G145942
Review Report on TMCO5A Target / Biomarker Content of Review Report on TMCO5A Target / Biomarker
TMCO5A
Other Name(s): Transmembrane and coiled-coil domain-containing protein 5A (isoform 1) | TMC5A_HUMAN | transmembrane and coiled-coil domains 5 | Transmembrane and coiled-coil domain-containing protein 5A | testicular tissue protein Li 205 | Transmembrane and coiled-coil domains 5A, transcript variant 1 | TMCO5A variant 1 | Transmembrane and coiled-coil domains 5 | TMCO5 | transmembrane and coiled-coil domains 5A

TMCO5A: A Transmembrane and Coiled-Coil Domain-Containing Protein: Potential Drug Target or Biomarker

TMCO5A (Transmembrane and coiled-coil domain-containing protein 5A, isoform 1) is a protein that has been identified as a potential drug target or biomarker. TMCO5A is a member of the superfamily of transmembrane proteins, which are involved in various physiological processes in the cell. It is characterized by the presence of a transmembrane domain and a coiled-coil domain. The transmembrane domain is responsible for the protein's maintainability, while the coiled-coil domain is involved in the protein's stability and interactions with other molecules.

TMCO5A is expressed in various tissues and cells in the body, including the brain, heart, and gastrointestinal tract. It is involved in various cellular processes, including cell signaling, neurotransmitter release, and sensory perception. TMCO5A has also been implicated in various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

Potential Drug Target

The potential drug target for TMCO5A is its involvement in neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These disorders are characterized by the progressive loss of brain cells, which can lead to the accumulation of neurotransmitters and the formation of aggregates that cause the symptoms. TMCO5A is involved in the production and degradation of neurotransmitters, which may be contributing to the neurodegeneration that occurs in these disorders.

In addition to its involvement in neurodegenerative disorders, TMCO5A may also be a potential drug target for other conditions, such as cancer and autoimmune diseases. For example, TMCO5A has been shown to be involved in the regulation of cell growth and differentiation, which may be relevant to the development of cancer. Additionally, TMCO5A has been implicated in the regulation of immune responses, which may be relevant to autoimmune diseases.

Biomarker

TMCO5A may also be a potential biomarker for various diseases. For example, the levels of TMCO5A have been shown to be decreased in individuals with Alzheimer's disease, which may be a potential diagnostic biomarker for this disorder. Additionally, TMCO5A has been shown to be involved in the regulation of neurotransmitter release, which may be relevant to the treatment of neurotransmitter-related disorders.

Conclusion

TMCO5A is a protein that has been identified as a potential drug target or biomarker. Its transmembrane and coiled-coil domain characteristics make it a promising candidate for drug development. TMCO5A's involvement in various cellular processes and its potential targets for neurodegenerative disorders, cancer, and autoimmune diseases make it an attractive target for research and development. Further studies are needed to fully understand TMCO5A's role in these conditions and to determine its potential as a drug target or biomarker.

Protein Name: Transmembrane And Coiled-coil Domains 5A

The "TMCO5A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMCO5A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TMCO5B | TMCO6 | TMED1 | TMED10 | TMED10P1 | TMED11P | TMED2 | TMED3 | TMED4 | TMED5 | TMED6 | TMED7 | TMED7-TICAM2 | TMED8 | TMED9 | TMEFF1 | TMEFF2 | TMEM100 | TMEM101 | TMEM102 | TMEM104 | TMEM105 | TMEM106A | TMEM106B | TMEM106C | TMEM107 | TMEM108 | TMEM109 | TMEM11 | TMEM114 | TMEM115 | TMEM116 | TMEM117 | TMEM119 | TMEM120A | TMEM120B | TMEM121 | TMEM121B | TMEM123 | TMEM125 | TMEM126A | TMEM126B | TMEM127 | TMEM128 | TMEM129 | TMEM130 | TMEM131 | TMEM131L | TMEM132A | TMEM132B | TMEM132C | TMEM132D | TMEM132D-AS1 | TMEM132E | TMEM132E-DT | TMEM133 | TMEM134 | TMEM135 | TMEM138 | TMEM139 | TMEM139-AS1 | TMEM140 | TMEM141 | TMEM143 | TMEM144 | TMEM145 | TMEM147 | TMEM147-AS1 | TMEM14A | TMEM14B | TMEM14C | TMEM14DP | TMEM14EP | TMEM150A | TMEM150B | TMEM150C | TMEM151A | TMEM151B | TMEM154 | TMEM156 | TMEM158 | TMEM160 | TMEM161A | TMEM161B | TMEM161B-DT | TMEM161BP1 | TMEM163 | TMEM164 | TMEM165 | TMEM167A | TMEM167AP2 | TMEM167B | TMEM168 | TMEM169 | TMEM17 | TMEM170A | TMEM170B | TMEM171 | TMEM174 | TMEM175